Phillip N Newsome

35PUBLICATIONS
155CO-AUTHORS
Metabolic medicineDisease surveillanceCardiology (incl. cardiovascular diseases)English languagePharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (35)

|Aug 31, 2026
Upcoming therapies for steatotic liver disease: Translating breakthroughs into clinical practice.

|Jun 20, 2025
Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease.

Jimmy Che-To Lai, Boyu Yang, Hye Won Lee

|Jun 11, 2025
Cardiovascular Risk Assessment Tools are Insufficient for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.

A Sidney Barritt, Elliot B Tapper, Philip N Newsome

|Feb 19, 2025
NAFLD vs MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)-Why the Need for a Change of Nomenclature?

Amalia Gastaldelli, Philip N Newsome

|Oct 16, 2024
Semaglutide 2.4 mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial.

Philip N Newsome, Arun J Sanyal, Kristiane A Engebretsen

|Oct 03, 2024
Evaluation of Gremlin-1 as a therapeutic target in metabolic dysfunction-associated steatohepatitis.

Paul Horn, Jenny Norlin, Kasper Almholt

Pageof 6

Frequent Collaborators

7 joint publications

Vincent Wai-Sun Wong

7 joint publications

Jörn M Schattenberg

5 joint publications

Jérôme Boursier

4 joint publications

Elisabetta Bugianesi